Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy

AIDS

Volumn 15, Issue 17, 2001, Pages 2325-2327

  Antinori, Andrea ^a   Liuzzi, Giuseppina ^a   Cingolani, Antonella ^a   Bertoli, Ada ^a   Di Giambenedetto, Simona ^a   Trotta, Maria P ^a   Rizzo, Maria G ^a   Girardi, Enrico ^a   De Luca, Adrea ^a   Perno, Carlo F ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; POINT MUTATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT FAILURE; VIREMIA; VIRUS MUTANT; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; POINT MUTATION; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 0035941384     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200111230-00017     Document Type: Article

References (13)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre
3. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure
4. CD4-cell count in HIV-1 A-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) Swiss HIV Cohort Study
5. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
6. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
7. Human immunodeficiency virus type 1 protease inhibitor modulates activation of perpheral blood CD4+ T cells and decrease their susceptibility to apoptosis in vitro and in vivo
8. High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy
9. Nonnucleoside reverse transcriptase inhibitor resistance
10. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of Rnase H cleavage that correlate with HIV-1 replication fitness in cell culture
11. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy
12. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
13. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy